Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 4Radiotherapy 3Cyclophosphamide 3Carmustine 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3sargramostim 2aldesleukin 2Thalidomide 2Paclitaxel 2Gadolinium DTPA 2Filgrastim 2Donepezil 2Biopsy 2temsirolimus 1surufatinib 1plerixafor 1omburtamab I-131 1ganitumab 1gallium Ga 68 dotatate 1gadobutrol 1gadobenic acid 1entinostat 1cixutumumab 1carboxyamido-triazole 1azurin (50-77) 1antineoplaston AS 2-1 1antineoplaston A10 1adavosertib 1Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Eflornithine × Sarcoma × Clear all
NCT06465199 2026-04-13

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡